ArticleFrontiers in pediatrics2026
Serum sST2 and MR-ProADM in pediatric acute rheumatic fever: association with cardiac involvement and clinical risk stratification.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute rheumatic fever (ARF) remains a major cause of acquired heart disease in children, particularly in low- and middle-income countries. Cardiac involvement is the main determinant of long-term morbidity and mortality; however, early evaluation relies heavily on echocardiography, which may not always be readily accessible. Therefore, there is a need for adjunctive biomarkers to support clinical assessment and risk stratification. Methods: This case-control study included 38 pediatric patients diagnosed with ARF and 38 age- and sex-matched healthy controls. Serum levels of soluble suppression of tumorigenicity-2 (sST2) and mid-regional pro-adrenomedullin (MR-ProADM) were measured using enzyme-linked immunosorbent assay. Cardiac involvement was assessed by echocardiography and further categorized as mild or no involvement vs. moderate-to-severe involvement. Nonparametric tests, receiver operating characteristic (ROC) analysis, and multivariate logistic regression were performed. Results: Both sST2 and MR-ProADM levels were significantly higher in patients with ARF compared to controls ( Conclusion: sST2 and MR-ProADM are elevated in pediatric ARF and reflect systemic inflammatory and cardiovascular processes. While they are not substitutes for echocardiographic evaluation, sST2 in particular may provide additional information in identifying patients with more clinically significant cardiac involvement. These biomarkers may serve as supportive tools for clinical assessment and early risk stratification, especially in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.